Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 5/20 | 0.63 |
| ▸ | NPC1 | O15118 | 6/20 | 0.61 |
| ▸ | RAB9A | P51151 | 6/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.61 |
| ▸ | PPARG | P37231 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.56 |
| ▸ | CASP3 | P42574 | 1/20 | 0.56 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.56 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.56 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.56 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | AR | P10275 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5954366 | 1.00 | LTA4H (0.63) | LTA4HNPC1RAB9ASMN1; SMN2PPARG | |
| SCHEMBL7418008 | 0.89 | LTA4H (0.60) | LTA4HNPC1RAB9ASMN1; SMN2PPARG | |
| SCHEMBL13399685 | 0.87 | LTA4H (0.59) | LTA4HNPC1RAB9ASMN1; SMN2PPARG | |
| SCHEMBL5955251 | 0.86 | LMNA (0.66) | LTA4HNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL5955247 | 0.86 | LMNA (0.66) | LTA4HNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL9059240 | 0.85 | CTSV (0.56) | LTA4HMAOB | |
| SCHEMBL9059239 | 0.85 | CTSV (0.56) | LTA4HMAOB | |
| SCHEMBL7468581 | 0.83 | LTA4H (0.58) | LTA4HNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL13399690 | 0.82 | MAOB (0.59) | LTA4HNPC1RAB9ASMN1; SMN2PPARG | |
| SCHEMBL15153602 | 0.82 | FFAR1 (0.69) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060025589-A1 | 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes | LABORATOIRES FOURNIER S.A. (FR) | 2006-02-02 | — | — | US | disclosed |
| EP-1546111-A2 | 2-THIOHYDANTOINE DERIVATIVE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF DIABETES | LABORATOIRES FOURNIER S.A. (FR) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004031160-A2 | 2-THIOHYDANTOINE DERIVATIVE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF DIABETES | LABORATOIRES FOURNIER S.A. (FR) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025589-A1 | 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes | LIPC, CYP4F2, SLC5A2 | LTA4H 141/4885NPC1 206/4885RAB9A 3994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.